查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595202

乙醯胺酚靜脈靜脈注射市場：依適應症、應用、最終用途分類 - 2025-2030 年全球預測

Paracetamol IV Market by Indication (Pain, Pyrexia/Fever), Application (Non-surgical, Surgical), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年乙醯胺酚靜脈注射市場價值為94079萬美元，預計到2024年將達到100813萬美元，複合年成長率為7.64%，預計到2030年將達到157545萬美元。

靜脈注射乙醯胺酚通常用作鎮痛和解熱劑，特別是在無法口服給藥的臨床環境中，靜脈注射可快速緩解疼痛和發燒。在手術、急診和嚴重監護環境中需要靜脈注射乙醯胺酚，在這些環境中即時控制疼痛至關重要，這使其成為醫院和專科診所的重要選擇。乙醯胺酚靜脈注射不僅用於緩解疼痛，還用於退燒和術後疼痛管理，使其成為手術全期醫療照護的重要組成部分。隨著醫療保健領域對有效疼痛管理的需求不斷增加，靜脈靜脈注射乙醯胺酚的最終用途正在擴展到醫院、門診診所和門診手術中心。

主要市場統計
基準年[2023] 94079萬美元
預測年份 [2024] 1,008.13 百萬美元
預測年份 [2030] 15.7545億美元
複合年成長率（%） 7.64%

乙醯胺酚靜脈注射市場的成長受到醫療保健支出增加、外科手術數量增加以及對疼痛管理通訊協定認知不斷增強的強烈影響。此外，新興國家醫療保健基礎設施的擴張正在為市場參與企業和現有參與者創造有利可圖的機會。為了抓住這些機會，公司可能會專注於透過聯合研究和銷售合作夥伴關係來提高產品可用性，特別是在人口稀少的市場。儘管存在這些成長要素，但市場仍面臨一些限制，例如與藥物過量相關的副作用、嚴格的監管要求以及阻礙市場擴張的替代鎮痛藥的競爭。

該領域的創新可能包括配方改進，以提高藥物療效、減少副作用並延長靜脈注射配方的保存期限。此外，藥物輸送系統的進步，例如智慧輸注技術，可能會提供競爭優勢。對患者量身定做的給藥方案的研究以及人工智慧驅動工具的整合以監測患者的反應可以進一步推進其應用和廣泛使用。該市場的特點是適度分散，主要參與者不斷透過策略聯盟和研發來競爭擴張。富有洞察力的分析和持續創新對於克服挑戰並釋放乙醯胺酚靜脈靜脈注射市場的開拓潛力至關重要。

市場動態：快速發展的乙醯胺酚靜脈靜脈注射市場的關鍵市場洞察

供需的動態交互作用正在改變靜脈注射乙醯胺酚市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 指定疾病和病症的盛行率不斷增加
    • 增加靜脈注射乙醯胺酚的使用以減少手術後的發燒
    • 加強對乙醯胺酚的使用以減少鴉片類藥物對疼痛管理的依賴
  • 市場限制因素
    • 多種學名藥的可用性
  • 市場機會
    • 政府措施和活性化的研發活動
    • 靜脈注射乙醯胺酚與非類固醇消炎劑(NSAID) 或麻醉藥合併使用
  • 市場挑戰
    • 缺乏經驗豐富的醫療保健專業人員

波特五力：駕馭乙醯胺酚靜脈靜脈注射市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解乙醯胺酚靜脈注射市場的外部影響

外部宏觀環境因素在塑造乙醯胺酚靜脈靜脈注射市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解乙醯胺酚靜脈靜脈注射市場的競爭狀況

對乙醯胺酚靜脈注射市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣乙醯胺酚靜脈靜脈注射市場供應商績效評估

FPNV 定位矩陣是評估乙醯胺酚靜脈靜脈注射市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製乙醯胺酚靜脈注射市場的成功之路

對乙醯胺酚靜脈注射市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 徵兆的疾病和症狀的盛行率增加
      • 手術後增加靜脈注射乙醯胺酚的使用以緩解發燒
      • 加強對乙醯胺酚的使用以減少疼痛管理中對鴉片類藥物的依賴
    • 抑制因素
      • 多種學名藥的可用性
    • 機會
      • 增加政府措施和研發活動
      • 將靜脈注射乙醯胺酚與非類固醇消炎劑(NSAID) 和麻醉藥合併使用
    • 任務
      • 缺乏經驗豐富的醫療保健專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章乙醯胺酚靜脈注射市場依適應症分類

  • 疼痛
  • 發燒

第7章乙醯胺酚靜脈注射市場：依應用分類

  • 非手術的
  • 外科手術

第8章乙醯胺酚靜脈靜脈注射市場：依最終用途分類

  • 診所
  • 醫院

第9章 北美、南美乙醯胺酚靜脈注射市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區乙醯胺酚靜脈注射市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東及非洲乙醯胺酚靜脈注射市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aurobindo Pharma Ltd.
  • Biological E. Limited
  • Cfl Pharmaceuticals Limited
  • Changshu Huagang Pharmaceuticals Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Geno Pharmaceuticals Private Limited
  • Hebei Jiheng Pharmaceutical Co.,Ltd.
  • Huzhou Konch Pharmaceutical Co., Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt PLC
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zhejiang Kangle Pharmaceutical Co., Ltd.
Product Code: MRR-F927BA4629AD

The Paracetamol IV Market was valued at USD 940.79 million in 2023, expected to reach USD 1,008.13 million in 2024, and is projected to grow at a CAGR of 7.64%, to USD 1,575.45 million by 2030.

Paracetamol IV, often used as an analgesic and antipyretic, is administered intravenously for rapid relief from pain and fever, particularly in clinical settings where oral administration is not feasible. The necessity of Paracetamol IV arises in surgical, emergency, and critical care scenarios where immediate pain management is vital, making it a crucial option in hospitals and specialty clinics. Its application is not only limited to pain relief but also spans the management of fever and post-operative pain, making it indispensable in perioperative care. As demand for effective pain management in healthcare rises, the end-use scope for Paracetamol IV is broadening, spanning hospitals, outpatient clinics, and ambulatory surgery centers.

KEY MARKET STATISTICS
Base Year [2023] USD 940.79 million
Estimated Year [2024] USD 1,008.13 million
Forecast Year [2030] USD 1,575.45 million
CAGR (%) 7.64%

Market growth for Paracetamol IV is strongly influenced by increasing healthcare expenditure, rising surgical procedures, and growing awareness regarding pain management protocols. Furthermore, the expansion of healthcare infrastructure in emerging economies presents lucrative opportunities for market entrants and existing players. To capture these opportunities, companies could focus on increasing product availability through collaborations or distribution partnerships, particularly in underpenetrated markets. Despite these growth drivers, the market faces limitations such as adverse effects associated with overdosage, stringent regulatory requirements, and competition from alternative analgesics, which can hinder its expansion.

Innovation in this sector could involve enhancing drug formulation to increase efficacy, reduce side effects, or extend the shelf life of the IV form. Additionally, advancements in drug delivery systems, such as smart infusion technology, can present a competitive edge. Research into patient-tailored dosing regimens and the integration of AI-driven tools for monitoring patient response could further refine its application and uptake. The market is characterized by moderate fragmentation with key players constantly vying for expansion through strategic collaborations and R&D. Insightful analysis and continuous innovation are crucial for navigating the challenges and tapping into the untapped potential of the Paracetamol IV market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Paracetamol IV Market

The Paracetamol IV Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of indicative diseases and conditions
    • Increasing use of paracetamol IV in relieving fever in post-surgical procedures
    • Enhanced usage of acetaminophen to reduce the dependence on opioids for pain management
  • Market Restraints
    • Availability of multiple generic products
  • Market Opportunities
    • Government initiatives and rising research and development activities
    • Use of paracetamol IV in combination with non-steroidal anti-inflammatory drugs (NSAID) and narcotics
  • Market Challenges
    • Lack of experienced healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Paracetamol IV Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Paracetamol IV Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Paracetamol IV Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Paracetamol IV Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Paracetamol IV Market

A detailed market share analysis in the Paracetamol IV Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Paracetamol IV Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Paracetamol IV Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Paracetamol IV Market

A strategic analysis of the Paracetamol IV Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Paracetamol IV Market, highlighting leading vendors and their innovative profiles. These include Aurobindo Pharma Ltd., Biological E. Limited, Cfl Pharmaceuticals Limited, Changshu Huagang Pharmaceuticals Co., Ltd., Dr. Reddy's Laboratories Ltd., Geno Pharmaceuticals Private Limited, Hebei Jiheng Pharmaceutical Co.,Ltd., Huzhou Konch Pharmaceutical Co., Ltd., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zhejiang Kangle Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Paracetamol IV Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Pain and Pyrexia/Fever.
  • Based on Application, market is studied across Non-surgical and Surgical.
  • Based on End-use, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of indicative diseases and conditions
      • 5.1.1.2. Increasing use of paracetamol IV in relieving fever in post-surgical procedures
      • 5.1.1.3. Enhanced usage of acetaminophen to reduce the dependence on opioids for pain management
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of multiple generic products
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives and rising research and development activities
      • 5.1.3.2. Use of paracetamol IV in combination with non-steroidal anti-inflammatory drugs (NSAID) and narcotics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of experienced healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Paracetamol IV Market, by Indication

  • 6.1. Introduction
  • 6.2. Pain
  • 6.3. Pyrexia/Fever

7. Paracetamol IV Market, by Application

  • 7.1. Introduction
  • 7.2. Non-surgical
  • 7.3. Surgical

8. Paracetamol IV Market, by End-use

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Paracetamol IV Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Paracetamol IV Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Paracetamol IV Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aurobindo Pharma Ltd.
  • 2. Biological E. Limited
  • 3. Cfl Pharmaceuticals Limited
  • 4. Changshu Huagang Pharmaceuticals Co., Ltd.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Geno Pharmaceuticals Private Limited
  • 7. Hebei Jiheng Pharmaceutical Co.,Ltd.
  • 8. Huzhou Konch Pharmaceutical Co., Ltd.
  • 9. Lupin Pharmaceuticals, Inc.
  • 10. Mallinckrodt PLC
  • 11. Novartis AG
  • 12. Sanofi S.A.
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Zhejiang Kangle Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PARACETAMOL IV MARKET RESEARCH PROCESS
  • FIGURE 2. PARACETAMOL IV MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARACETAMOL IV MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARACETAMOL IV MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARACETAMOL IV MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARACETAMOL IV MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PARACETAMOL IV MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PARACETAMOL IV MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PARACETAMOL IV MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PARACETAMOL IV MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARACETAMOL IV MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARACETAMOL IV MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARACETAMOL IV MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARACETAMOL IV MARKET DYNAMICS
  • TABLE 7. GLOBAL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARACETAMOL IV MARKET SIZE, BY PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARACETAMOL IV MARKET SIZE, BY PYREXIA/FEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARACETAMOL IV MARKET SIZE, BY NON-SURGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARACETAMOL IV MARKET SIZE, BY SURGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARACETAMOL IV MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARACETAMOL IV MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PARACETAMOL IV MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PARACETAMOL IV MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM PARACETAMOL IV MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM PARACETAMOL IV MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM PARACETAMOL IV MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. PARACETAMOL IV MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. PARACETAMOL IV MARKET, FPNV POSITIONING MATRIX, 2023